VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested of $30.97 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested · last filed 2024-02-27
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-12-31 was $330.00.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-09-30 was $7.26K.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-06-30 was -$1.20K.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2023-03-31 was $24.58K.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2023 was $30.97K, a 24.93% increase from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2022 was $24.79K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 12 month |
|---|---|---|---|---|
| 2023-12-31 | $330.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $7.59K derived: sum of 2 quarters · filed 2024-02-27 | $6.39K derived: sum of 3 quarters · filed 2024-02-27 | $30.97K 10-K · filed 2024-02-27 |
| 2023-09-30 | $7.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $6.06K derived: sum of 2 quarters · filed 2023-11-06 | $30.64K 10-Q · filed 2023-11-06 | $30.64K derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | -$1.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $23.38K 10-Q · filed 2023-08-08 | $23.38K derived: sum of 3 quarters · filed 2024-02-27 | |
| 2023-03-31 | $24.58K 10-Q · filed 2023-05-08 | $24.58K derived: sum of 2 quarters · filed 2024-02-27 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $24.79K 10-K · filed 2024-02-27 | ||
| 2022-09-30 | $24.79K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |